MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Pancreatic Ductal
  • Deoxycytidine
  • Pancreatic Neoplasms
  • Pyrazoles
  • Pyrimidines

abstract

  • These results indicate that MK-1775 selectively synergizes with GEM to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

publication date

  • May 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3307341

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-2580

PubMed ID

  • 21389100

Additional Document Info

start page

  • 2799

end page

  • 806

volume

  • 17

number

  • 9